HeartBeam, Inc. (BEAT)
| Market Cap | 22.16M -60.6% |
| Revenue (ttm) | n/a |
| Net Income | -20.30M |
| EPS | -0.50 |
| Shares Out | 56.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 542,050 |
| Open | 0.3960 |
| Previous Close | 0.3981 |
| Day's Range | 0.3857 - 0.4024 |
| 52-Week Range | 0.3550 - 4.0000 |
| Beta | -0.77 |
| Analysts | Buy |
| Price Target | 3.50 (+789.91%) |
| Est. Earnings | Nov 12, 2026 |
About BEAT
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart’s electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician port... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BEAT stock is "Buy." The 12-month stock price target is $3.5, which is an increase of 789.91% from the latest price.
News
HeartBeam announces HEADSTART-ACS study completed enrollment
HeartBeam (BEAT) announced that the HEADSTART-ACS study, conducted at the National Cardiovascular Center Harapan Kita in Jakarta, Indonesia, has completed enrollment ahead of schedule. The study enrol...
HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology
SANTA CLARA, Calif.--(BUSINESS WIRE)--HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology.
HeartBeam joins European EXIT-CVD Research Consortium
HeartBeam (BEAT) is a contributing partner in the launch of the EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative and industry partners. The research consortium i...
HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome.
Why These 3 Penny Stocks Are on Investors’ Radar Today
WISeSat.Space Holdings ($SAIQ), Veea Inc. ($VEEA), and HeartBeam Inc. ($BEAT) are among the penny stocks to watch on October 6, according to TipRanks’ Penny Stock Screener Tool. A penny stock typicall...
Why Is Penny Stock HeartBeam (BEAT) Up Nearly 60% Today?
HeartBeam stock was up nearly 60% on Monday thanks to an FDA update for the company’s HeartBeam System.
HeartBeam receives FDA Breakthrough Device Designation for HeartBeam System
HeartBeam (BEAT) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device Designation, BDD, for the HeartBeam System as a tool for assessing potential heart attacks a...
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment.
HeartBeam downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded HeartBeam (BEAT) to Neutral from Buy without a price target The company issued a letter to shareholders describing its decision to not build a large commercial organization…
HeartBeam says redirecting resources to myocardial infarction detection
HeartBeam (BEAT) issued a letter to shareholders from its Executive Chairman Richard Ferrari, and President and Founder, Branislav Vajdic, PhD, which read, in part, “HeartBeam is at an inflection poin...
HeartBeam, Inc. Letter to Shareholders
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. Letter to Shareholders.
HeartBeam reports Q2 EPS (10c) vs (15c) last year
“Every 40 seconds, someone suffers from a heart attack, and we believe HeartBeam’s (BEAT) technology, incorporating our signal capture technology TriCor, is the best way to evaluate the real extent…
HeartBeam sees Q3 cash flow in line with Q2
Third quarter 2026 cash outflow is expected to be in line with the second quarter of 2026, due to the short-term impact of updating the Company’s cost structure. Baseline fourth…
HeartBeam Earnings Call Transcript: Q2 2026
Heart attack detection initiatives advanced with FDA pre-submission and strong pilot study results. Commercial rollout in concierge practices and integrated networks is underway, with reduced cash outflows and an extended runway into 2027. Adjusted net loss improved year-over-year.
HeartBeam Quarterly report: Q2 2026
HeartBeam has published its Q2 2026 quarterly earnings report on August 13, 2026.
HeartBeam Slides: Q2 2026
HeartBeam has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
HeartBeam Earnings release: Q2 2026
HeartBeam released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
HeartBeam Reports Second Quarter 2026 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2026 Results.
HeartBeam Transcript: AGM 2026
The meeting confirmed a quorum, elected seven directors, and approved the auditor for 2026. The proposal to amend the equity plan was not approved. Shareholders were directed to the website for further updates and a quarterly call in August.
HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time.
HeartBeam initiated with a Buy at Maxim
Maxim initiated coverage of HeartBeam (BEAT) with a Buy rating and $2 price target
HeartBeam awarded U.S. patent for ECG device capabilities
HeartBeam (BEAT) announced the allowance of a new U.S. patent that significantly expands the capabilities of its credit card-sized, cable-free ECG device. The patent covers the integration of acoustic...
HeartBeam completes patient enrollment in ALIGN-ACS pilot study
HeartBeam (BEAT) announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. Enrollment was completed ahead of the Company’s pre...
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule.
HeartBeam Proxy statement: Proxy filing
HeartBeam filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.